ClinicalTrials.gov
ClinicalTrials.gov Menu

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (STARBEAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02006641
Recruitment Status : Completed
First Posted : December 10, 2013
Results First Posted : February 20, 2018
Last Update Posted : February 20, 2018
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
H. Lundbeck A/S

Brief Summary:
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Placebo Drug: Idalopirdine Phase 3

Detailed Description:
The study consisted of a screening period (up to 2-week period from screening to randomization), a 24-week double-blind treatment period with placebo or idalopirdine 10 mg/day or 30 mg/day as adjunctive therapy to donepezil 10 mg/day, and a 4-week safety follow-up period following study completion or withdrawal from treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 858 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
Study Start Date : February 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo adjunct to 10 mg Donepezil
Drug: Placebo
Once daily, matching placebo capsules, orally

Experimental: Idalopirdine 10 mg
Idalopirdine adjunct to 10 mg Donepezil
Drug: Idalopirdine
Once daily, encapsulated tablets, orally
Other Name: Lu AE58054

Experimental: Idalopirdine 30 mg
Idalopirdine adjunct to 10 mg Donepezil
Drug: Idalopirdine
Once daily, encapsulated tablets, orally
Other Name: Lu AE58054




Primary Outcome Measures :
  1. Change in Cognition [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.

    The Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment).



Secondary Outcome Measures :
  1. Change in Daily Functioning [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.

    The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability).


  2. Change in Global Impression [ Time Frame: Baseline and Week 24 ]

    Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.

    The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening).


  3. Change in Behavioural Disturbance [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score.

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome).


  4. Change in Individual Behavioural Disturbance Items [ Time Frame: Baseline and Week 24 ]

    Change in single NPI item scores at Week 24.

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome.


  5. Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline

    The Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 [occasionally] to 4 [very frequent]) and severity (a 3-point scale from 1 [mild] to 3 [marked]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome.


  6. Number of Participants With Clinical Improvement [ Time Frame: Week 24 ]
    Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4])

  7. Number of Participants With Clinical Worsening [ Time Frame: Week 24 ]
    Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes [change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4])

  8. Change in Cognitive Aspects of Mental Function [ Time Frame: Baseline and Week 24 ]
    Change from baseline to Week 24 in Mini Mental State Examination (MMSE). The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).

  9. Change in Health-related Quality of Life (EQ-5D) Utility Score [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score

    The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome.


  10. Change in Health-related Quality of Life (EQ-5D VAS) [ Time Frame: Baseline and Week 24 ]

    Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).

    The EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has a knowledgeable and reliable caregiver.
  • The patient is an outpatient.
  • The patient has probable AD.
  • The patient has mild to moderate AD.
  • Stable treatment with donepezil.
  • The patient, if a woman, must have had her last natural menstruation ≥24 months prior to baseline, OR be surgically sterile.
  • The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.

Exclusion Criteria:

  • The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.
  • The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.
  • The patient has evidence of clinically significant disease.
  • The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
  • The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.

Other inclusion and exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02006641


  Hide Study Locations
Locations
United States, Arizona
US338
Phoenix, Arizona, United States
United States, Arkansas
US342
Fayetteville, Arkansas, United States
United States, California
US322
Anaheim, California, United States
US305
Carson, California, United States
US346
Costa Mesa, California, United States
US327
Fullerton, California, United States
US315
Lomita, California, United States
US351
Oceanside, California, United States
US307
Redlands, California, United States
US301
Santa Rosa, California, United States
United States, Connecticut
US337
New London, Connecticut, United States
US332
Stamford, Connecticut, United States
United States, Florida
US308
Delray Beach, Florida, United States
US320
Hallandale Beach, Florida, United States
US347
Hialeah, Florida, United States
US340
Lake Worth, Florida, United States
US303
Miami, Florida, United States
US313
Miami, Florida, United States
US335
Naples, Florida, United States
US345
Orange City, Florida, United States
US309
Palm Beach Gardens, Florida, United States
US302
Sunrise, Florida, United States
United States, Georgia
US304
Atlanta, Georgia, United States
US360
Augusta, Georgia, United States
US318
Decatur, Georgia, United States
United States, Louisiana
US334
Lake Charles, Louisiana, United States
United States, Massachusetts
US350
Belmont, Massachusetts, United States
US344
Boston, Massachusetts, United States
United States, Minnesota
US310
Saint Paul, Minnesota, United States
United States, Mississippi
US321
Hattiesburg, Mississippi, United States
United States, Missouri
US330
Creve Coeur, Missouri, United States
United States, New Jersey
US339
Manchester, New Jersey, United States
United States, New York
US312
Staten Island, New York, United States
United States, North Carolina
US316
Charlotte, North Carolina, United States
US336
Winston-Salem, North Carolina, United States
United States, Ohio
US323
Cincinnati, Ohio, United States
US349
Cleveland, Ohio, United States
US306
Columbus, Ohio, United States
US352
Lakewood, Ohio, United States
United States, Oklahoma
US333
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
US314
Allentown, Pennsylvania, United States
US324
Pittsburgh, Pennsylvania, United States
US341
Pittsburgh, Pennsylvania, United States
US325
Reading, Pennsylvania, United States
United States, South Carolina
US319
Port Royal, South Carolina, United States
United States, Tennessee
US356
Cordova, Tennessee, United States
United States, Texas
US343
Fort Worth, Texas, United States
US354
Houston, Texas, United States
Argentina
AR303
Banfield, Argentina
AR301
Ciudad Autonoma Buenos Aires, Argentina
AR304
Ciudad Autonoma Buenos Aires, Argentina
AR308
Ciudad Autonoma Buenos Aires, Argentina
AR311
Ciudad Autonoma Buenos Aires, Argentina
AR313
Ciudad Autonoma Buenos Aires, Argentina
AR314
Ciudad Autonoma Buenos Aires, Argentina
AR315
Ciudad Autonoma Buenos Aires, Argentina
AR312
Ciudad Autonoma de Buenos Aires, Argentina
AR309
Cordoba, Argentina
AR307
Córdoba, Argentina
AR305
Godoy Cruz, Argentina
AR310
Mendoza, Argentina
AR302
Santa Fe, Argentina
AR306
Santiago del Estero, Argentina
Brazil
BR307
Curitiba, Brazil
BR309
Curitiba, Brazil
BR301
Rio de Janeiro, Brazil
BR306
Rio de Janeiro, Brazil
BR308
San Paolo, Brazil
Canada
CA301
Halifax, Canada
CA302
Kelowna, Canada
CA306
Montreal, Canada
CA304
Qubec, Canada
CA303
Sherbrooke, Canada
CA305
Toronto, Canada
Croatia
HR304
Zabok, Croatia
HR301
Zagreb, Croatia
HR302
Zagreb, Croatia
HR303
Zagreb, Croatia
Czechia
CZ305
Brno, Czechia
CZ306
Chocen, Czechia
CZ309
Chocen, Czechia
CZ308
Pardubice, Czechia
CZ310
Praha 10 - Strasnice, Czechia
CZ304
Praha 10, Czechia
CZ307
Praha 2, Czechia
CZ301
Praha 6, Czechia
CZ303
Praha 6, Czechia
CZ302
Rychnov nad Kneznou, Czechia
Estonia
EE301
Tallinn, Estonia
EE303
Tallin, Estonia
EE302
Tartu, Estonia
Finland
FI302
Kuopio, Finland
FI303
Oulu, Finland
FI301
Turku, Finland
France
FR301
Bordeaux, France
FR308
Bron, France
FR307
Colmar cedex, France
FR304
Dijon, France
FR309
Elancourt, France
FR302
Marseille cedex 5, France
FR303
Nice Cedex 1, France
FR306
Reims, France
FR305
Rouen, France
Hungary
HU304
Budapest, Hungary
HU305
Budapest, Hungary
HU301
Esztergom, Hungary
HU303
Gyor, Hungary
HU302
Szeged, Hungary
Ireland
IE301
Cork, Ireland
Israel
IL302
Haifa, Israel
IL303
Holon, Israel
IL304
Ramat Gan, Israel
Italy
IT306
Brescia, Italy
IT309
Brescia, Italy
IT311
Genova, Italy
IT312
Monza, Italy
IT302
Naples, Italy
IT313
Palermo, Italy
IT307
Perugia, Italy
IT301
Pisa, Italy
IT305
Roma, Italy
IT308
Roma, Italy
IT304
Torino, Italy
IT310
Torrette, Italy
Korea, Republic of
KR303
Busan, Korea, Republic of
KR301
Incheon, Korea, Republic of
KR308
Seongnam-si, Korea, Republic of
KR302
Seoul, Korea, Republic of
KR304
Seoul, Korea, Republic of
KR305
Seoul, Korea, Republic of
KR306
Seoul, Korea, Republic of
KR307
Seoul, Korea, Republic of
KR309
Seoul, Korea, Republic of
Lithuania
LT302
Kaunas, Lithuania
LT303
Kaunas, Lithuania
LT301
Vilnius, Lithuania
LT304
Vilnius, Lithuania
Poland
PL301
Bialystok, Poland
PL304
Bydgoszcz, Poland
PL308
Gdynia, Poland
PL309
Krakow, Poland
PL302
Lodz, Poland
PL310
Lubin, Poland
PL306
Lublin, Poland
PL307
Oswiecim, Poland
PL303
Poznan, Poland
Portugal
PT301
Amadora, Portugal
PT302
Coimbra, Portugal
Taiwan
TW301
Kaohsiung, Taiwan
TW302
Kaohsiung, Taiwan
TW303
Taichung, Taiwan
TW304
Taipei, Taiwan
TW305
Taipei, Taiwan
United Kingdom
GB307
Amersham, United Kingdom
GB301
Glasgow, United Kingdom
GB303
London, United Kingdom
GB308
London, United Kingdom
GB306
Plymouth, United Kingdom
GB305
Preston, United Kingdom
GB304
Southampton, United Kingdom
GB302
Swindon, United Kingdom
GB309
Warrington, United Kingdom
Sponsors and Collaborators
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.
Investigators
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT02006641     History of Changes
Other Study ID Numbers: 14862A
2012-004764-22 ( EudraCT Number )
First Posted: December 10, 2013    Key Record Dates
Results First Posted: February 20, 2018
Last Update Posted: February 20, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents